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H]thymidine incorporation by 50%, i.e., to levels comparable to those achieved by addition of either AG-1478 or GM-6001. Utilizing Akt small-interfering RNA targeted to Akt1 and Akt2, Akt protein knockdown dramatically inhibited p70S6K1 and S6 ribosomal protein phosphorylation. In contrast, AG-1478 or Akt gene silencing exerted no detectable inhibitory effect on ANG II-induced extracellular signalregulated kinase 1/2 phosphorylation in IEC-18 cells. Taken together, our results demonstrate that EGFR transactivation mediates ANG II-stimulated mitogenesis through the PI3-kinase/Akt/mTOR/ p70S6K1 signaling pathway in IEC-18 cells.
IEC-18 cells; mitogen-activated protein kinase; mitogen/extracellular signal-regulated kinase; protein kinase B; epidermal growth factor receptor; phosphatidylinositol 3-kinase THE SEQUENTIAL PROLIFERATION, lineage-specific differentiation, migration, and cell death of epithelial cells of the intestinal mucosa is a tightly regulated process that is modulated by a broad spectrum of regulatory peptides (5, 26, 50) , but the signal transduction pathways involved remain incompletely understood. The nontransformed IEC-18 cells, derived from rat small intestinal crypt (40) , have provided an in vitro model to examine intestinal epithelial cell migration, differentiation, and proliferation (16, 17, 28) . These cells are undifferentiated, as judged by morphological and functional criteria; they resemble stem cells and thus may serve as a model to study the crypt stem cell (51) . The importance of examining this compartment is highlighted by recent reports suggesting that the initial mutant cell in the pathogenesis of colorectal adenoma may arise from the crypt stem cell compartment (37, 55) .
Neuropeptides and vasoactive peptides that signal through G protein-coupled receptors (GPCRs), characterized by seventransmembrane helixes, act as potent cellular growth factors for a variety of cell types (43, 44, 45, 47) . In particular, GPCRs and their agonists play a crucial role in the regulation of multiple functions in the gastrointestinal tract, including cell proliferation, motility, and transport. We have recently demonstrated that the vasoactive peptide ANG II and the neuropeptide arginine vasopressin induce DNA synthesis and cell proliferation in intestinal epithelial IEC-18 cells (8, 9) . Some of the key molecules that mediate the growth-promoting signal of these GPCR agonists in IEC-18 cells have been identified. ANG II induces a dramatic increase in protein kinase C (PKC)-dependent protein kinase D (PKD) activation in IEC-18 cells via the angiotensin type 1 (AT 1 ) receptor coupled to G q (7) . ANG II also stimulates PKC-dependent tyrosine phosphorylation of proline-rich tyrosine kinase 2 (Pyk2), a nonreceptor tyrosine kinase that has been implicated as an upstream element in extracellular signal-regulated kinase (ERK) 1/2 activation, in IEC-18 cells (56) . Accordingly, this GPCR agonist stimulates PKC-dependent ERK activation in these cells. Interestingly, inhibition of the PKC or ERK pathway in these cells reduces ANG II-induced DNA synthesis by 50 -60% (8, 9) . These findings not only indicated that ANG II-induced DNA synthesis is partially dependent on ERK and PKC but also prompted us to hypothesize that another pathway, in addition to ERK and PKC, plays a substantial role in AT 1 -mediated mitogenesis of IEC-18 cells.
Recently, it has been shown that a variety of GPCR agonists also induce a rapid increase in epidermal growth factor receptor (EGFR) tyrosine autophosphorylation in several cell types (10 -12, 29, 52) , termed transactivation (6, 36) . This receptor cross talk can occur via extracellular release of EGFR ligands at the cell surface (36) by matrix metalloproteases that belong to the ADAM (a disintegrin and metalloprotease) family of zinc-dependent proteases. GPCR-induced EGFR transactivation leads to the phosphorylation of specific tyrosine residues within the EGFR cytoplasmic domain that act as docking sites for effector molecules, resulting in activation of downstream signaling pathways. However, it is increasingly recognized that the contribution of EGFR transactivation to agonist-induced mitogenic signaling is strongly dependent on cell context. The experiments presented in this study were designed to examine the role of EGFR tyrosine kinase and its downstream targets in mediating the transition from the G 0 /G 1 phase into S phase in response to the potent mitogen ANG II in the normal intestinal epithelial IEC-18 cells.
In contrast to many cell types in which EGFR contributes to mitogenesis via the Ras/Raf/MEK/ERK pathway, the results presented in this study demonstrate that EGFR transactivation mediates ANG II-induced DNA synthesis in IEC-18 cells via activation of the phosphatidylinositol (PI)3-kinase/Akt/mTOR/ p70S6K1 pathway.
MATERIALS AND METHODS
Cell culture. IEC-18 cells were purchased from American Type Culture Collection. Stock cultures were maintained in DMEM supplemented with 5% FBS in a humidified atmosphere containing 10% CO 2-90% air at 37°C. For experiments, cells were plated in 100-mm dishes at 3 ϫ 10 5 cells/dish in DMEM containing 5% FBS, allowed to grow to confluency (5-7 days), and then changed to serum-free DMEM for 18 -24 h before the experiment.
Western blot analysis for protein kinase phosphorylation. Serumstarved cultures of IEC-18 cells grown on 100-mm dishes were washed two times with DMEM and then treated as described in the individual experiments. The cells were lysed in 2ϫ SDS-PAGE sample buffer. After SDS-PAGE, proteins were transferred to Immobilon-P membranes (Millipore) and blocked by 3-to 6-h incubation with 5% nonfat milk in PBS, pH 7.2. Membranes were then incubated overnight with the respective phosphospecific antibodies (see Materials). The same membranes were stripped and probed in a similar fashion with the respective polyclonal antibody for total protein.
Bound primary antibodies to immunoreactive bands were visualized by enhanced chemiluminescence detection with horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat antibodies. Autoradiograms were scanned using a GS-710 scanner (Bio-Rad), and the labeled bands were quantified using the Quantity One software program (Bio-Rad).
Assays of EGFR tyrosine phosphorylation. Serum-starved cultures of IEC-18 cells were washed two times with serum-free DMEM and then incubated for 1 h at 37°C with or without inhibitors, as indicated. Cells were then treated for 2 min with agonists. Cell stimulation was terminated by transferring the cultures to ice, aspirating the medium, and lysing the cells in 1 ml ice-cold modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris ⅐ HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM Pefabloc SC, 1 mg/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na 3VO4, and 1 mM NaF). The cell suspension was then mixed for 20 min at 4°C to lyse the cells, and cell lysates were clarified by centrifugation at 15,000 rpm for 10 min. To measure EGFR tyrosine phosphorylation, the supernatants were transferred to new microtubes and mixed with 10 g/ml polyclonal ␣-EGFR at 4°C overnight. Immunocomplexes were captured by adding 100 l protein A-agarose beads for 1 h, and then agarose beads were collected by pulse centrifugation (0.5 min at 14,000 rpm). The beads were washed three times with ice-cold RIPA buffer and subsequently solubilized in 100 l 2ϫ SDS-PAGE sample buffer. Tyrosine-phosphorylated EGFR was detected by immunoblotting using 4G10 monoclonal antibody (MAb).
Assay of DNA synthesis. Confluent and serum-starved cultures of IEC-18 cells were washed two times with DMEM and incubated with DMEM/Waymouth's medium (1:1, vol/vol) and various additions, as described in the legends for Figs. 1-9. After 15 h of incubation at 37°C, [ 3 H]thymidine (0.2 Ci/ml, 1 M) was added, and the cultures were incubated for a further 4 h at 37°C. Cultures were then washed two times with PBS and incubated in 5% TCA at 4°C for 20 min to remove acid-soluble radioactivity, washed with ethanol, and solubilized in 1 ml of 2% Na 2CO3 and 0.1 M NaOH. The acid-insoluble radioactivity was determined by scintillation counting in 6 ml Beckman Readysafe.
Flow cytometric/cell cycle analysis. The proportion of cells in the G 0/G1, S, G2, and M phases of the cell cycle was determined by flow cytometric analysis. Confluent and serum-starved cultures of IEC-18 cells were washed two times with DMEM and incubated with DMEM/Waymouth's medium (1:1, vol/vol) containing various additions, as described in the legends for Figs. 1-9. After 19 h of incubation at 37°C, cultures were washed two times with PBS. Cells were then detached by treatment with trypsin (0.025%), suspended in DMEM containing 10% FBS, and centrifuged at 1,000 g for 5 min. Cells (10 6 ) were then resuspended and stained by adding 1 ml of a hypotonic DNA staining buffer containing propidium iodide (0.1 mg/ml), sodium citrate (1 mg/ml), RNase A (20 g/ml), and Triton X-100 (0.3%). Samples were kept at 4°C, protected from light for 30 min, and analyzed on a FACScan (Becton-Dickinson, Franklin Lakes, NJ), using the software CELLQuest version 3.3 and Modfit 3.1 (Verity Software House, Topsham, ME).
Akt small-interfering RNA. (Fig. 1A, top) , separated by SDS-PAGE, and further analyzed by Western blotting using anti-Tyr(P) MAb. As shown in Fig. 1A , ANG II stimulated a rapid EGFR tyrosine phosphorylation in IEC-18 cells, reaching a maximum within 30 s and remaining elevated for at least 60 min.
Pretreatment of IEC-18 cells with the selective EGFR tyrosine kinase inhibitors tyrphostin AG-1478 or the structurally unrelated compound 56 (20) , both at 250 nM, completely prevented ANG II-induced increase in tyrosine phosphorylation of EGFR induced by ANG II. Stripping the same blots and reprobing with anti-EGFR antibody confirmed that similar amounts of EGFR protein were recovered after ANG II stimulation (Fig. 1, A and B, bottom) . The results presented in Fig.  1, A and B, demonstrate that ANG II markedly stimulates EGFR tyrosine kinase activity in IEC-18 cells.
To determine whether the cross talk between EGFR and GPCRs is mediated by extracellular release of EGFR ligands at the cell surface in IEC-18 cells, cultures of these cells were preincubated with GM-6001 (also known as Ilomastat or galardin), a broad-spectrum matrix metalloproteinase (MMP) inhibitor (1, 21, 49) . Serum-starved cultures of IEC-18 cells were preincubated with either control medium or medium containing 10 M GM-6001 for 1 h and then stimulated with ANG II. The concentration of GM-6001 used in these experiments (10 M) was shown to inhibit MMP-1, -2, and -3 (21) .
Pretreatment of cells with GM-6001 suppressed the increase in EGFR tyrosine phosphorylation induced by ANG II stimulation (Fig. 1B) . This result indicates that ANG II-stimulated EGFR tyrosine phosphorylation depends on the activity of GM-6001-sensitive metalloprotease(s) to mediate extracellular release of EGFR ligands.
Exogenously added heparin has been shown to inhibit EGFR transactivation by competing with cell surface-associated heparan sulfate proteoglycans for HB-EGF-binding (25, 41) . Here we used heparin to determine whether ANG II stimulates EGFR tyrosine phosphorylation through HB-EGF release in IEC-18 cells. Serum-starved cultures of these cells were pretreated with 50 g/ml heparin before stimulation with ANG II, HB-EGF, or EGF. We verified that heparin inhibited HB-and EGF-induced EGFR tyrosine phosphorylation, whereas EGFinduced EGFR tyrosine phosphorylation was not affected in IEC-18 cells (Fig. 1C) . Interestingly, pretreatment with heparin significantly reduced ANG II-induced EGFR tyrosine phosphorylation. This result combined with our results with GM-6001 suggests that HB-EGF is required for ANG II-stimulated EGFR transactivation in IEC-18 cells.
ANG II-stimulated DNA synthesis is dependent on EGFR tyrosine kinase activity. We recently demonstrated that ANG II acts as a potent growth factor for IEC-18 cells, promoting exit from G 0 /G 1 and entry into the S phase in IEC-18 cells (8), but the precise mechanism(s) that mediate ANG II-induced mitogenesis remains incompletely understood. To examine whether EGFR transactivation contributes to ANG II-induced DNA synthesis, serum-deprived cultures of IEC-18 cells were preincubated for 1 h with the selective EGFR tyrosine kinase inhibitor tyrphostin AG-1478 at various concentrations (30 -500 nM) before stimulation with ANG II. As shown in Fig. 2A , treatment with tyrphostin AG-1478 markedly attenuated [ 3 H]thymidine incorporation in response to ANG II stimulation in a concentration-dependent fashion. A maximal inhibitory effect (ϳ50%) was achieved at 100 nM tyrphostin AG-1478.
To substantiate that the effects on [ 3 H]thymidine incorporation reflect an increase in DNA replication through the S phase of the cell cycle rather than alterations in transport and/or phosphorylation of 3 H]thymidine incorporation data, treatment with tyrphostin AG-1478 reduced the shift toward S phase in response to ANG II stimulation by ϳ50% (Fig. 2B ).
Because our results showed that the broad-spectrum metalloprotease inhibitor GM-6001 also prevented EGFR transactivation in response to ANG II, we tested whether ANG IIstimulated DNA synthesis would be similarly inhibited by cell exposure to this antagonist. As shown in Fig. 2C , pretreatment with GM-6001 reduced [ 3 H]thymidine incorporation in response to ANG II stimulation by ϳ50%, an inhibitory effect identical to that induced by the EGFR kinase inhibitor tyrphostin AG-1478. The results presented in Fig. 2 indicate that a substantial component (ϳ50%) of the mitogenic stimulus induced by ANG II in intestinal epithelial IEC-18 cells is mediated by EGFR transactivation.
ANG II stimulates EGFR-dependent Akt activation. Next, we attempted to identify the mechanism(s) by which EGFR contributes to ANG II-induced DNA synthesis in IEC-18 cells. In a variety of cell types, EGFR transactivation mediates mitogenic stimulation by GPCRs through ERK1/2 activation via a well-defined mechanism involving SOS-Grb2/Ras/Raf and mitogen/extracellular signal-regulated kinase (MEK; see Refs. 46 and 54). However, our recent results with IEC-18 cells suggested that a different mechanism is operational downstream of EGFR in these intestinal epithelial cells. Specifically, ANG II-induced ERK activation in IEC-18 cells was mediated primarily by PKCs rather than EGFR, and inhibition of the ERK pathway attenuated (but did not eliminate) ANG II-induced DNA synthesis (also see below). These findings suggested that a pathway other than ERK plays a substantial role in mitogenesis in response to ANG II in these epithelial cells.
In addition to the well-recognized role of the ERKs in mitogenic signaling, the PI3-kinase pathway has also been implicated in signal transduction linked to cell division, differentiation, and tumorigenesis (4). Signaling by PI3-kinases is mediated by 3-phosphoinositide binding to the PH domains of both Akt and 3Ј-phosphoinositide-dependent kinase (PDK) 1, thereby inducing their translocation to the plasma membrane where PDK1 phosphorylates and activates Akt. These findings prompted us to determine whether ANG II-induced EGFR tyrosine kinase acts via the PI3-kinase/Akt pathway in IEC-18 cells.
To determine whether ANG II stimulates the PI3-kinase pathway in IEC-18 cells, we first examined whether ANG II induces the activation of the key PI3-kinase target Akt in these cells. Akt, translocated to the plasma membrane in response to products of PI3-kinase, is activated by phosphorylation at Thr 308 by PDK1 (2) and by phosphorylation within the COOH terminus at Ser 473 by a less well-defined protein kinase referred to as PDK2 (33) . Recently, DNA-dependent protein kinase has been implicated as PDK2 (15) . Serum-starved cultures of IEC-18 cells were stimulated with 50 nM ANG II for various times (0 -60 min) and lysed, and Western blot analyses were performed using an MAb that recognizes Akt phosphorylated at Ser 473 , a major regulatory phosphorylation site commonly used as a marker for increased signaling via this pathway. As (10 6 ) were then resuspended and stained by 1 ml of a hypotonic DNA staining buffer containing propidium iodide (0.1 mg/ml), sodium citrate (1 mg/ml), RNase A (20 g/ml), and Triton X-100 (0.3%). Samples were kept at 4°C, protected from light for 30 min, and analyzed on a FACScan (Becton-Dickinson). The profiles represent the number of cells as a function of relative DNA content. In each case, the percentages of cells in G0/G1 (first peak), S (hatched area well-defined in ANG II-treated cells), and G2/M (second peak) are indicated. Results shown are representative of 3 independent experiments. C: effect of AG-1478 and GM-6001 on DNA synthesis in response to ANG II. Confluent and serum-starved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/Waymouth's medium containing 50 nM ANG II either without or with 250 nM AG-1478 and/or 10 M GM-6001, as indicated. [ 3 H]thymidine incorporation into acid-precipitable material was measured as described. Results are expressed as a percentage of the maximum increase Ϯ SE (n ϭ 3) obtained with 50 nM ANG II.
shown in Fig. 3A (34) , a site of importance in the regulation of mTOR function (30, 42) , via the tuberous sclerosis complex/Ras homolog enriched in brain pathway (32) . To determine whether ANG II can stimulate mTOR activation in IEC-18 cells, lysates of these cells stimulated with 50 nM ANG II for various times (0 -60 min) were subjected to Western blot analyses using an antibody that detects mTOR phosphorylated at Ser 2448 . As shown in Fig. 4A , ANG II stimulation rapidly induced mTOR Ser 2448 phosphorylation in IEC-18 cells. A half-maximal effect was achieved at 2.5 min, and a maximum was reached within 5 min.
p70S6K1 is a major downstream target of the PI3-kinase/ Akt/mTOR pathway that is implicated in cell growth and G 1 cell cycle progression (39) . Rapamycin, a macrolide immunosuppressant that complexes with FK506-binding protein (FKBP12), is a potent and selective inhibitor of TOR proteins and signaling to p70S6K1. The activity of p70S6K1 is controlled by multiple phosphorylation events located within the catalytic, linker, and pseudosubstrate domains (39) . Rapamycin-sensitive phosphorylation of Thr 389 by mTOR in the linker region is thought to be required for subsequent PDK1-mediated phosphorylation of Thr 229 in the catalytic domain (35, 38) . To determine whether ANG II activates p70S6K1 in IEC-18 cells, serum-starved cultures of these cells were stimulated with 50 nM ANG II for various times (0 -60 min) and lysed, and the extracts were subjected to Western blot analyses using an antibody that recognizes p70S6K1 phosphorylated at Thr 389 , a major phosphorylation site that correlates closely with kinase activity (53) . As shown in Fig. 4B , ANG II stimulation rapidly induced p70S6K1 phosphorylation at Thr 389 . A half-maximal effect was achieved at 2.5 min, and maximal phosphorylation was reached within 10 min. Thus the kinetics of p70S6K1 phosphorylation at Thr 389 parallels that of mTOR phosphorylated at Ser 2448 . To determine whether a functional mTOR was required for the ANG II-induced phosphorylation of p70S6K1 at Thr 389 , serum-starved cultures of IEC-18 cells were pretreated with rapamycin before stimulation with ANG II. As shown in Fig. 5A , rapamycin completely blocked ANG II-induced p70S6K1 phosphorylation at Thr 389 . To substantiate that p70S6K1 activation occurs downstream of PI3-kinase in ANG II-stimulated IEC-18 cells, serumstarved cultures of IEC-18 cells were pretreated with either LY-294002 or wortmannin before stimulation with 50 nM Because our results demonstrated that the activation of the PI3-kinase/Akt pathway by ANG II is mediated by EGFR transactivation, we next tested whether ANG II-induced p70S6K1 activation also requires a functional EGFR pathway. As shown in Fig. 5A , ANG II-induced p70S6K1 phosphorylation at Thr 389 was dramatically reduced by prior treatment of the cells with either tyrphostin AG-1478 (250 nM) or compound 56 (500 nM). The Western blot was also probed for total p70S6K1 after stripping. Note that p70S6K1 protein was present in all lanes, including those that did not show any phosphorylation.
Because our results demonstrated that the activation of the PI3-kinase/Akt/p70S6K1 pathway by ANG II is mediated by EGFR transactivation, we next tested whether ANG II-induced p70S6K1 activation also requires HB-EGF activity. Serumstarved cultures of IEC-18 cells were pretreated with heparin before ANG II, HB-EGF, or EGF stimulation. As shown in Fig. 5B , heparin inhibited ANG II-and HB-EGF-induced p70S6K1 phosphorylation at Thr 389 , whereas EGF-induced p70S6K1 phosphorylation was not affected. This result, combined with the experiments shown in Fig. 1 
, suggests that HB-EGF is required for ANG II-stimulated HB-and EGFmediated EGFR transactivation in IEC-18 cells. ANG II induces S6 ribosomal protein phosphorylation through EGFR, PI3-kinase, and p70S6K1 in IEC-18 cells.
To substantiate that phosphorylation of p70S6K1 at Thr 389 faithfully reflects p70S6K1 catalytic activity in IEC-18 cells stimulated with ANG II, we next examined the phosphorylation of the 40S ribosomal protein subunit S6, which is a well-established downstream target of p70S6K1 in intact cells. Phosphorylation of S6 by p70S6K1 correlates with an increase in translation, particularly of mRNAs with an oligopyrimidine tract in their 5Ј-untranslated regions (3 (Fig. 6B) . 
Akt gene silencing inhibits ANG II-stimulated p70S6K1 and S6 ribosomal protein phosphorylation in IEC-18 cells.
To substantiate that Akt mediates p70S6K1 activation and S6 phosphorylation, we utilized gene silencing by RNA interference. Subconfluent cultures of IEC-18 cells were transiently transfected with Akt siRNA that targets Akt1 and Akt2 (27) . To test the specificity of the siRNA, subconfluent cultures of IEC-18 cells were transfected with a nontargeted negative control duplex. As shown in Fig. 6C , Akt protein level in IEC-18 cells transfected with Akt siRNA was dramatically reduced compared with cells transfected with nontargeted negative control duplex. Akt gene silencing abrogated ANG IIinduced p70S6K1 Thr 389 phosphorylation (Fig. 6C ) and dramatically reduced ANG II-induced S6 ribosomal protein phosphorylation at Ser 235 and Ser 236 compared with nontargeted negative control duplex transfected cells (Fig. 6C) . In contrast, ANG II-induced ERK1/2 phosphorylation was not affected in IEC-18 cells transfected either with Akt siRNA or nontargeted negative control duplex (Fig. 6C) . These results further demonstrate the selectivity of Akt gene silencing and indicate that ANG II induces ERK1/2 phosphorylation via a distinct signal- ing pathway, separate from the PI3-kinase/Akt/mTOR/ p70S6K1 pathway.
ANG II induces EGFR transactivation and ERK activation through parallel pathways. If PI3-kinase and p70S6K1 lie downstream of EGFR in ANG II-stimulated IEC-18 cells, inhibitors of these kinases should not interfere with EGFR transactivation. As shown in Fig. 7A , stimulation of IEC-18 cell cultures with ANG II induced a marked increase in the tyrosine phosphorylation of the EGFR, in agreement with the results presented in Fig. 1 . Pretreatment of these cells with either LY-294002 or rapamycin did not produce any detectable effect on the increase in EGFR tyrosine phosphorylation induced by ANG II. These results substantiate that PI3-kinase and p70S6K1 lie downstream of EGFR in ANG II-stimulated cells.
In many cellular systems, EGFR transactivation mediates activation of the ERK pathway in response to GPCR agonists. It is conceivable that ANG II-induced EGFR transactivation not only leads to the activation of the PI3-kinase/Akt/TOR/ p70S6K1 pathway but also mediates ERK activation. To directly test this possibility, we examined whether EGFR transactivation mediates ANG II-induced ERK1/2 phosphorylation. Serum-deprived cultures of IEC-18 cells were pretreated with either tyrphostin AG-1478 or compound 56 before addition of ANG II. The activated forms of ERK1/2 were monitored by using a specific anti-phospho-p44/p42 mapk MAb that recognizes only the activated forms phosphorylated on Thr 202 and Tyr 204 . As shown in Fig. 7B , ANG II-induced ERK1/2 activation was unaffected by either of the EGFR tyrosine kinase inhibitors, demonstrating that ERK is not rapidly activated by Fig. 7 . Effects of inhibition of EGFR tyrosine kinase, PI3-kinase, mTOR, and MEK on EGFR tyrosine phosphorylation and ERK activation in IEC-18 cells. A: ANG II-induced EGFR tyrosine phosphorylation is not affected by inhibition of PI3-kinase or mTOR. Confluent and serum-starved cultures of IEC-18 cells were stimulated for 2 min with 50 nM ANG II after 1 h preincubation with 10 M LY-294002 or 10 nM rapamycin, as indicated. The EGFR was immunoprecipitated using a polyclonal EGFR antibody and resolved by SDS-PAGE. Proteins were transferred to Immobilon-P membranes, and then tyrosine phosphorylated EGFR was detected using 4G10 anti-Tyr(P) MAb. Membranes were then stripped and reprobed with anti-EGFR. The results are representative of 3 independent experiments. B: ANG II induces p42 mapk (ERK2) and p44 mapk (ERK1) phosphorylation in a time-dependent manner. Confluent and serum-starved cultures of IEC-18 cells were incubated for 1 h with 250 nM AG-1478, 1 nM rapamycin, 10 M LY-294002, or 2.5 M U-0126. Control cells received equivalent amount of solvent. The cultures were subsequently left unstimulated (Ϫ) or stimulated (ϩ) for 2.5 min with 50 nM ANG II at 37°C. Western blot analysis using a specific anti-phospho-ERK1/2 MAb that recognizes only the activated forms phosphorylated on Thr 202 and Tyr 204 was performed after lysis of the cells with 2ϫ sample buffer, as described in MATERIALS AND METHODS. The Western blot was also probed for total ERK, showing equal loading. C: ANG II-induced EGFR tyrosine phosphorylation is not affected by MEK inhibitors. Confluent and serum-starved cultures of IEC-18 cells were stimulated for 2 min with 50 nM ANG II after 1 h preincubation with 2.5 M U-0126 or 10 M PD-98059, as indicated. The EGFR was immunoprecipitated using a polyclonal EGFR antibody and resolved by SDS-PAGE. Proteins were transferred to Immobilon-P membranes, and then tyrosine-phosphorylated EGFR was detected using 4G10 anti-Tyr(P) MAb. Membranes were then stripped and reprobed with anti-EGFR. The results are representative of 3 independent experiments. ANG II via EGFR transactivation. Furthermore, inhibition of PI3-kinase or p70S6K1 had no effect on ANG II-induced ERK1/2 activation, supporting the notion that these pathways act in parallel (Fig. 7B) . In addition, ANG II-induced EGFR transactivation was not prevented by cell treatment with the MEK inhibitors U-0126 or PD-98059, demonstrating that the ERKs are not upstream of EGFR transactivation (Fig. 7C) . The results shown in Fig. 7 provide further support for the notion that the EGFR/PI3-kinase/Akt/mTOR/p70S6K1 pathway and the MEK/ERK pathway act in parallel in ANG II-stimulated IEC-18 cells.
Rapamycin (Fig. 8B) . The results presented in Fig. 8 ANG II stimulation in a concentration-dependent fashion, with a maximal inhibitory effect at ϳ50%. The results presented in Fig. 8C show that inhibition of the ERK pathway by treatment of IEC-18 cells with the MEK inhibitor U-0126 also attenuated [ 3 H]thymidine incorporation in response to ANG II stimulation by ϳ50%. Given these results, we hypothesized that inhibition of both EGFR tyrosine kinase and ERK would lead to an additive inhibitory effect, suggesting that these distinct pathways contribute to ANG II-induced mitogenesis in IEC-18 cells.
As shown in Fig. 8D , pretreatment with the combination of selective EGFR tyrosine kinase inhibitor tyrphostin AG-1478 and selective MEK inhibitor U-0126 gave an additive inhibitory effect that nearly abolished ANG II-induced DNA synthesis. Taken together, these results strongly suggest that ANG II-induced DNA synthesis requires two distinct pathways involving the MEK/ERK and the EGFR/PI3-kinase/Akt/mTOR/ p70S6K1, as shown schematically in Fig. 9 .
DISCUSSION
The proliferation of epithelial cells of the intestinal mucosa is regulated by a broad spectrum of regulatory peptides acting through both tyrosine kinase receptors and heptahelical GPCRs (5, 26, 50) . The understanding of the mechanisms involved requires the identification of the signal transduction pathways that mediate intestinal epithelial cell proliferation.
We have recently demonstrated that the addition of ANG II, at nanomolar concentrations, induces DNA synthesis and cell proliferation in intestinal epithelial IEC-18 cells via the AT 1 receptor in the absence of any other exogenously added growth factor. ANG II induces a dramatic increase in PKC-dependent PKD activation in these cells (7) and stimulates PKC-dependent tyrosine phosphorylation of Pyk2, a nonreceptor tyrosine kinase that has been implicated as an upstream element in ERK1/2 activation (56). Accordingly, ANG II stimulates PKCdependent ERK activation, a major pathway leading to cell cycle activation and cell proliferation. Interestingly, inhibition of the ERK pathway in these cells reduces ANG II-induced DNA synthesis by 50 -60% (8). These findings not only indicated that ANG II-induced DNA synthesis is partially dependent on ERK and PKC but also raise the intriguing possibility that another pathway, in addition to ERK and PKC, plays a substantial role in AT 1 -mediated mitogenesis of IEC-18 cells. The experiments presented in this study were designed to identify the pathway that, together with ERK, drives cell cycle progression in ANG II-stimulated IEC-18 cells.
Activation of a variety of GPCRs has been shown to stimulate the tyrosine kinase activity of the EGFR in several cell types (10 -12, 29, 52 ), a process termed transactivation (6, 36) . As a first step to evaluate the role of EGFR transactivation in mediating ANG II-induced mitogenesis in IEC-18 cells, we demonstrated that stimulation with this agonist induced a striking increase in EGFR tyrosine phosphorylation. This response was prevented by cell exposure to the selective EGFR tyrosine kinase inhibitor AG-1478 or by the broad-spectrum metalloprotease inhibitor GM-6001, suggesting that proteolytic release of EGFR ligand(s) is involved. We have further shown that heparin pretreatment significantly reduced ANG II-induced EGFR tyrosine phosphorylation (Fig. 1C) and ANG II-induced EGFR signaling (p70S6K1 phosphorylation), whereas ANG II-induced ERK activation was not affected (Fig. 5B) . These results combined with those obtained by using the broad-spectrum metalloproteinase inhibitor GM-6001 suggest that HB-EGF is required for ANG II-stimulated EGFR transactivation and EGFR-dependent downstream signaling in IEC-18 cells.
Furthermore, treatment with EGFR tyrosine kinase inhibitors or GM-6001 also attenuated (by ϳ50%) DNA synthesis Fig. 9 . Signal transduction pathways involved in ANG II-induced mitogenesis in IEC-18 cells. This scheme summarizes our results demonstrating that ANG II-induced mitogenesis is dependent on 2 independent, distinct pathways, involving the protein kinase C (PKC)/MEK/p44/p42 mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase (ERK)] and the EGFR/PI3-kinase/Akt/mTOR/p70S6K1 pathways. ANG II also stimulates calcium-and PKC-dependent tyrosine phosphorylation of proline-rich tyrosine kinase 2 (Pyk2), a nonreceptor tyrosine kinase that has been implicated as an upstream element in p44/p42 MAPK activation, in IEC-18 cells (56) . The inhibitors used in this study to block specific pathways are shown as marked by boxes. The dotted lines imply the existence of intermediary steps leading to the subsequent event; solid lines represent direct consequence of the previous effector. GF-1 or GF-109203X (also known as bisindolylmaleimide I) is a PKC inhibitor. PLC, phospholipase C; PI3K, PI3-kinase; DAG, diacylglycerol; Ins (1, 4, 5) In many cell types, the EGFR has been proposed to mediate Ras/ERK1/2 activation in response to GPCR activation, and the ERK pathway has been implicated in mitogenic signal transduction by many stimuli (13, 14, 18, 19) . For example, in vascular smooth muscle cells (13, 14) , pancreatic stellate cells (19) , and breast cancer cells (18) , ANG II has been shown to stimulate cell cycle progression through EGFR-dependent ERK activation.
In contrast, our results with IEC-18 cells indicate that EGFR transactivation contributes to ANG II-induced mitogenesis primarily through activation of the PI3-kinase/Akt/p70S6K1 pathway, whereas PKC (not EGFR tyrosine kinase) mediates the ANG II-stimulated ERK pathway. Specifically, several lines of evidence support this conclusion as follows: 1) suppression of EGFR tyrosine kinase had no effect on ANG II-stimulated ERK1/2 activation in IEC-18 cells, in agreement with our recent results indicating that ANG II-induced ERK activation is mediated primarily by PKCs in these cells; 2) activation of PI3-kinase results in production of lipid-derived second messengers that promote PDK1-mediated activation of Akt. We demonstrated here that stimulation of IEC-18 cells with ANG II induced Akt phosphorylation at Ser 473 , a major regulatory phosphorylation site required for kinase activity. Akt activation in response to ANG II was completely inhibited by prior exposure of the cells to selective inhibitors of PI3-kinase (wortmannin, LY-294002) or EGFR tyrosine kinase (tyrphostin AG-1478); 3) another downstream effector of PI3-kinase implicated in cell cycle progression is p70S6K1. We showed that ANG II markedly stimulated p70S6K1 phosphorylation at Thr 389 , a major phosphorylation site that correlates closely with kinase activity, through an EGFR-, PI3-kinaseand mTOR-dependent pathway; and 4) siRNAs targeting Akt1 and Akt2 dramatically inhibited ANG II-induced p70S6K1 phosphorylation at Thr 389 and the phosphorylation at Ser We also produced several lines of evidence indicating that ANG II-induced activation of the PI3-kinase pathway contributes to cell cycle progression into DNA synthesis in IEC-18 cells. Specifically, we demonstrated that inhibition of PI3-kinase or mTOR/p70S6K1 by the specific immunosuppressant rapamycin reduced [ 3 H]thymidine incorporation by 50%, i.e., to levels comparable to those achieved by addition of either selective EGFR tyrosine kinase inhibitors or the broad-spectrum metalloprotease GM-6001. If PKC-dependent ERK activation and EGFR-dependent PI3-kinase signaling operate as independent pathways that contribute to ANG II-induced DNA synthesis in IEC-18 cells, we expect that simultaneous blockade of these pathways should produce additive inhibition of DNA synthesis. In line with this prediction, we show that treatment of IEC-18 cells with a combination of the EGFR tyrosine kinase inhibitor tyrphostin AG-1478 and the selective MEK inhibitor U-0126 produced an additive inhibitory effect that nearly abolished ANG II-induced DNA synthesis. Inhibition of either pathway alone reduced ANG II-stimulated DNA synthesis by ϳ50%. As depicted in Fig. 9 , we conclude that ANG II-stimulated mitogenesis in intestinal epithelial IEC-18 cells is mediated by the following two distinct signaling pathways: PKC-dependent MEK/ERK and an EGFR-dependent PI3-kinase/Akt/mTOR/p70S6K1, dissected in the present study.
Early studies demonstrated that AT 1 is the predominant ANG II receptor in the gastrointestinal tract, as revealed by in situ autoradiography (22) . ANG II has been shown to mediate epithelial sodium and water absorption in the jejunum, ileum, and distal colon (23, 24) , but the role of ANG II-induced AT 1 receptor signaling in intestinal epithelial cell proliferation and differentiation is much less defined. Collectively, our previous and present results demonstrate that ANG II is a potent growth factor for intestinal epithelial cells and identify some of the critical molecular events that mediate the mitogenic effect of ANG II in these cells. These results assume an added significance in view of recent reports demonstrating that 1) drugs blocking the biological activity of ANG II enhanced the antitumor effect of cyclooxygenase-2 inhibitors in colon carcinoma models, 2) the high frequency of activating mutations of PI3-kinase gene in human colorectal cancers, and 3) the evidence suggesting that inhibitors of ANG II generation (i.e., angiotensin I-converting enzyme) protect against risk of multiple cancers (31, 48, 57) .
